The global gynaecological cancer drugs market is expected to grow at a CAGR of 4.5% during the forecast period, to reach USD 3.2 billion by 2030. The growth of this market is driven by the increasing incidence of gynaecological cancers and the rising awareness about cancer prevention and treatment among women.
Alkylating agents are one of the most commonly used types of chemotherapy drugs for treating gynaecological cancers, which are expected to account for a significant share in this market during the forecast period. Alkylating agents are also used as adjuvant therapy in combination with other chemotherapeutic agents such as anthracyclines, plant alkaloids, antitumor antibiotics, and taxanes for treating various types of cancers including ovarian cancer and cervical cancer. Plant alkaloids are also widely used in chemotherapy treatments due to their low toxicity levels compared with other types of chemotherapeutic drugs such as alkylating agents or anthracyclines; they have been found effective against various types of cancers including ovarian cancer and cervical cancer. Antitumor antibiotics have been found effective against various types of cancers including breast carcinoma; they can be administered orally or intravenously depending on their type (e.g., doxorubicin) which makes them more convenient than other forms that need injections every day or week (e.g., cyclophosphamide). Taxanes have been found effective against various kinds o.
Some Of The Growth Factors Of This Market:
- The increasing number of women who are entering the workforce and delaying childbirth is also expected to drive growth in this market over the forecast period as it increases their risk for developing cancer later in life due to increased exposure to carcinogens such as tobacco smoke and radiation from medical imaging procedures such as CT scans or X-rays.
Industry Growth Insights published a new data on “Gynaecological Cancer Drugs Market”. The research report is titled “Gynaecological Cancer Drugs Market research by Types (Alkylating Agent, Plant Alkaloid, Anthracyclines, Antitumor Antibiotic, Others), By Applications (Hospital Pharmacies, Retail Pharmacies, E-commerce), By Players/Companies Roche Holdings, AstraZeneca, Sanofi, Eli Lilly, Pfizer, Takeda Pharmaceuticals, Bristol-Myers Squibb, Merck, Dr Reddy’s Laboratories, Johnson & Johnson, GlaxoSmithKline, Apotex, Hoffmann-La Roche, Novartis, Pfizer, Teva Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gynaecological Cancer Drugs Market Research Report
By Type
Alkylating Agent, Plant Alkaloid, Anthracyclines, Antitumor Antibiotic, Others
By Application
Hospital Pharmacies, Retail Pharmacies, E-commerce
By Companies
Roche Holdings, AstraZeneca, Sanofi, Eli Lilly, Pfizer, Takeda Pharmaceuticals, Bristol-Myers Squibb, Merck, Dr Reddy’s Laboratories, Johnson & Johnson, GlaxoSmithKline, Apotex, Hoffmann-La Roche, Novartis, Pfizer, Teva Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Gynaecological Cancer Drugs Market Report Segments:
The global Gynaecological Cancer Drugs market is segmented on the basis of:
Types
Alkylating Agent, Plant Alkaloid, Anthracyclines, Antitumor Antibiotic, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, E-commerce
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche Holdings
- AstraZeneca
- Sanofi
- Eli Lilly
- Pfizer
- Takeda Pharmaceuticals
- Bristol-Myers Squibb
- Merck
- Dr Reddy’s Laboratories
- Johnson & Johnson
- GlaxoSmithKline
- Apotex
- Hoffmann-La Roche
- Novartis
- Pfizer
- Teva Pharmaceutical
Highlights of The Gynaecological Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alkylating Agent
- Plant Alkaloid
- Anthracyclines
- Antitumor Antibiotic
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gynaecological Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gynaecological cancer drugs are medications used to treat cancers of the uterus, ovaries, and other parts of the female reproductive system. These drugs can be used in combination with other treatments or as stand-alone treatments.
Some of the key players operating in the gynaecological cancer drugs market are Roche Holdings, AstraZeneca, Sanofi, Eli Lilly, Pfizer, Takeda Pharmaceuticals, Bristol-Myers Squibb, Merck, Dr Reddy¢â‚¬â„¢s Laboratories, Johnson & Johnson, GlaxoSmithKline, Apotex, Hoffmann-La Roche, Novartis, Pfizer, Teva Pharmaceutical.
The gynaecological cancer drugs market is expected to grow at a compound annual growth rate of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Gynaecological Cancer Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Gynaecological Cancer Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Gynaecological Cancer Drugs Market - Supply Chain
4.5. Global Gynaecological Cancer Drugs Market Forecast
4.5.1. Gynaecological Cancer Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Gynaecological Cancer Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Gynaecological Cancer Drugs Market Absolute $ Opportunity
5. Global Gynaecological Cancer Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Gynaecological Cancer Drugs Market Size and Volume Forecast by Type
5.3.1. Alkylating Agent
5.3.2. Plant Alkaloid
5.3.3. Anthracyclines
5.3.4. Antitumor Antibiotic
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Gynaecological Cancer Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Gynaecological Cancer Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. E-commerce
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Gynaecological Cancer Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Gynaecological Cancer Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Gynaecological Cancer Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Gynaecological Cancer Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Gynaecological Cancer Drugs Demand Share Forecast, 2019-2026
9. North America Gynaecological Cancer Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Gynaecological Cancer Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Gynaecological Cancer Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. E-commerce
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Gynaecological Cancer Drugs Market Size and Volume Forecast by Type
9.7.1. Alkylating Agent
9.7.2. Plant Alkaloid
9.7.3. Anthracyclines
9.7.4. Antitumor Antibiotic
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Gynaecological Cancer Drugs Demand Share Forecast, 2019-2026
10. Latin America Gynaecological Cancer Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Gynaecological Cancer Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Gynaecological Cancer Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. E-commerce
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Gynaecological Cancer Drugs Market Size and Volume Forecast by Type
10.7.1. Alkylating Agent
10.7.2. Plant Alkaloid
10.7.3. Anthracyclines
10.7.4. Antitumor Antibiotic
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Gynaecological Cancer Drugs Demand Share Forecast, 2019-2026
11. Europe Gynaecological Cancer Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Gynaecological Cancer Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Gynaecological Cancer Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. E-commerce
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Gynaecological Cancer Drugs Market Size and Volume Forecast by Type
11.7.1. Alkylating Agent
11.7.2. Plant Alkaloid
11.7.3. Anthracyclines
11.7.4. Antitumor Antibiotic
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Gynaecological Cancer Drugs Demand Share, 2019-2026
12. Asia Pacific Gynaecological Cancer Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Gynaecological Cancer Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Gynaecological Cancer Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. E-commerce
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Gynaecological Cancer Drugs Market Size and Volume Forecast by Type
12.7.1. Alkylating Agent
12.7.2. Plant Alkaloid
12.7.3. Anthracyclines
12.7.4. Antitumor Antibiotic
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Gynaecological Cancer Drugs Demand Share, 2019-2026
13. Middle East & Africa Gynaecological Cancer Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Gynaecological Cancer Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Gynaecological Cancer Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. E-commerce
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Gynaecological Cancer Drugs Market Size and Volume Forecast by Type
13.7.1. Alkylating Agent
13.7.2. Plant Alkaloid
13.7.3. Anthracyclines
13.7.4. Antitumor Antibiotic
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Gynaecological Cancer Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Gynaecological Cancer Drugs Market: Market Share Analysis
14.2. Gynaecological Cancer Drugs Distributors and Customers
14.3. Gynaecological Cancer Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche Holdings
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eli Lilly
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Takeda Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bristol-Myers Squibb
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Dr Reddys Laboratories
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Johnson & Johnson
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. GlaxoSmithKline
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Apotex
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Hoffmann-La Roche
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Novartis
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Pfizer
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Teva Pharmaceutical
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
